Look up one drug

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Mar-Quetiapine · DIN 02399849 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2013-07-30 Health Canada: Cancelled post market since 2026-03-06 · brand MAR-QUETIAPINE · ATC N05AH04 QUETIAPINE · form Tablet (immediate-release) · route Oral · ingredients QUETIAPINE (QUETIAPINE FUMARATE) 200 MG · company Marcan pharmaceuticals inc · schedule Prescription

DIN 02399849: Mar-Quetiapine Raw flags: sec3=Y Item: 281608193; group id 506; item number 1324; lccId None; manufacturer id MAR Source form: Tab; strength: 200mg Recorded listing: General benefit Source prices (unrounded): $0.2647; ministry $0.2647 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02399849 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88469

Interchangeable products

Act Quetiapine · DIN 02316110 · $0.2647 Apo-Quetiapine · DIN 02313936 · $0.2647 Apo-Quetiapine Fumarate · DIN 02501651 · $0.2647 Auro-Quetiapine · DIN 02390248 · $0.2647 Bio-Quetiapine · DIN 02447223 · $0.2647 Jamp Quetiapine Fumarate · DIN 02390167 · $0.2647 Jamp-Quetiapine · DIN 02330458 · $0.2647 Mint-Quetiapine · DIN 02438046 · $0.2647 PMS-Quetiapine · DIN 02296594 · $0.2647 Quetiapine · DIN 02317923 · $0.2647 Quetiapine · DIN 02353199 · $0.2647 Quetiapine Tablets · DIN 02387824 · $0.2647 Ran-Quetiapine · DIN 02397110 · $0.2647 Sandoz Quetiapine · DIN 02314010 · $0.2647 Seroquel · DIN 02236953 · $0.2647 Teva-Quetiapine · DIN 02284278 · $0.2647

Shortage status: active shortage (reported 2019-03-30, last updated 2019-03-31) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02399849

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2026-03-06 — choose a marketed DIN from the same-category list.